Clinical Implications of Updated Data from EHA 2024

Opinion
Video

Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.

Video content above is prompted by the following:

  • What Is your current strategy and treatment option for maintenance therapy in NDMM for transplant eligible??
  • Please share your thoughts on the updated data from CASSOPEIA. (Moreau P et al. EHA 2024, Abstract S204)
  • How does the data impact frontline treatment for transplant eligible NDMM?
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
Related Content
A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.

Belantamab Mafodotin Combo Regimens Accepted for Review in Japan in R/R MM

Harrison Widelitz
September 18th 2024
Article

A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.

Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma

Roman Fabbricatore
September 3rd 2024
Article

“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

Alexander Spira, MD, PhD, FACP;Millie Das, MD;Joshua K. Sabari, MD;Misako Nagasaka, MD
September 4th 2023
Podcast

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

MRD May Predict Improved Outcomes in Multiple Myeloma

MRD May Predict Improved Outcomes in Multiple Myeloma

ONCOLOGY Staff
August 25th 2024
Article

Minimal residual disease as an end point in multiple myeloma has been widely discussed and was even a topic of a recent ODAC meeting.

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

ONCOLOGY Staff
August 23rd 2024
Article

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.